A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease—A Case Report

Bahar Kapoor Force, Tiphanie P. Vogel, Dang Nguyen, Kent A. Heck, Sherly Sebastian, Masayoshi Takashima, Daniel Yoshor, Susan L. SamsonFrontiers in Endocrinology 2020 · DOI

Abstract

Granulomatous hypophysitis (GrHy) is a rare inflammatory condition of the pituitary gland that can be idiopathic or secondary to systemic diseases like Crohn’s disease (CD). While corticosteroids are the standard first-line treatment, some cases are refractory. We report a case of a 43-year-old woman with CD and steroid-resistant GrHy who achieved complete clinical and radiographic resolution following treatment with the anti-tumor necrosis factor (TNF)-$\alpha$ agent, infliximab.

Introduction

Hypophysitis involves inflammation of the pituitary gland, leading to mass effect symptoms such as severe headaches and visual deficits, as well as life-threatening hormonal deficiencies. Granulomatous hypophysitis is a specific histologic subtype characterized by granulomas and multinucleated giant cells. When associated with Crohn’s disease, it represents an extra-intestinal manifestation of the systemic inflammatory process. Managing steroid-resistant cases remains a significant clinical challenge, necessitating personalized immunotherapy approaches.

Case Description

A 43-year-old woman with a 9-year history of ileal and colonic Crohn’s disease presented with severe headaches, visual disturbances, and symptoms of pituitary dysfunction, including secondary amenorrhea and fatigue. Initial hormonal testing confirmed hyperprolactinemia, secondary hypothyroidism, and adrenal insufficiency. MRI imaging revealed a 12 × 12 × 19 mm sellar mass abutting the optic chiasm, which was initially suspected to be a macroadenoma.

Histopathological Diagnosis

To differentiate the lesion from a neoplasm, the patient underwent an endoscopic transsphenoidal biopsy. The pathology revealed extensive granulomatous inflammation, confirming a diagnosis of granulomatous hypophysitis rather than a pituitary adenoma.

Histopathology of the pituitary biopsy showing characteristic granulomatous inflammation with multinucleated giant cells and histiocytes.

Therapeutic Intervention and Clinical Course

Following the diagnosis, the patient was started on high-dose prednisone. However, her symptoms worsened, and follow-up MRI showed an increase in the size of the inflammatory mass. She also developed symptoms of diabetes insipidus (polyuria and polydipsia).

Given her history of Crohn’s disease and the failure of corticosteroids, a personalized medicine approach was adopted. The patient was started on infliximab (an anti-TNF-$\alpha$ monoclonal antibody) in combination with azathioprine, therapies already indicated for her underlying Crohn's disease.

Results

The response to anti-TNF-$\alpha$ therapy was rapid and dramatic. Within three months, the patient's headaches and polyuria resolved, and her menstrual cycles resumed, indicating a partial restoration of the hypothalamic-pituitary-gonadal axis.

Serial MRI scans (A-E) demonstrating the clinical progression: (A) Baseline; (B) Post-biopsy; (C) Worsening after corticosteroid therapy; (D) Significant reduction 3 months after starting infliximab; (E) Complete resolution at 1.5 years.

Long-term follow-up at 1.5 years confirmed the durable resolution of the pituitary mass. Although the patient eventually transitioned to adalimumab due to infliximab-induced plaque psoriasis, her pituitary condition remained in complete remission.

Conclusion

This case represents the first reported successful use of anti-TNF-$\alpha$ therapy for granulomatous hypophysitis. The shared inflammatory pathways between Crohn’s disease and GrHy suggest that TNF-$\alpha$ inhibition may be a potent therapeutic option for steroid-resistant cases, potentially extending to idiopathic forms of the disease where TNF-$\alpha$ plays a key role in granuloma formation.

Summary updated

Abstract

<b>Background:</b> Hypophysitis is primary or idiopathic or secondary to another disease process. The histologic subtypes of hypophysitis are lymphocytic, granulomatous, xanthomatous, xanthogranulomatous, or IgG4-related. Granulomatous hypophysitis is the second most common form and is characterized by multinucleated giant cells with granulomas and histiocytes. It can be idiopathic or secondary to another process such as infection, sarcoidosis, vasculitis, dendritic cell disorders, Crohn's disease (CD) or a reaction to rupture of a Rathke's cyst or pituitary adenoma. We present a case of granulomatous hypophysitis in a patient with CD who had resistance to corticosteroids but a dramatic response to immunosuppressive therapy with anti-tumor necrosis factor (TNF)-α therapy. <b>Case description:</b> A 43-year-old woman with a 9-year history of ileal and colonic CD presented to the Pituitary Center with headaches, visual disturbance, fatigue, nausea, and secondary amenorrhea. She was not on active therapy for her CD at the time of presentation and had no gastrointestinal symptoms. Hormonal evaluation revealed hyperprolactinemia, secondary hypothyroidism and adrenal insufficiency. MRI revealed a 12 × 12 × 19 mm sellar lesion abutting the optic chiasm, reported as a macroadenoma. The patient underwent endoscopic transsphenoidal biopsy of the pituitary mass. Pathology revealed granulomatous hypophysitis. Evaluation for secondary causes of hypophysitis, apart from CD, was negative. Despite a course of high dose prednisone, her symptoms and MRI findings worsened and she developed symptoms consistent with diabetes insipidus. Using a personalized medicine approach, she was started on anti-(TNF)-α therapy with infliximab combined with azathioprine, which are indicated for treatment of CD. Her headaches and polyuria resolved and her menstrual cycles resumed. MRI at 3 months and more than 1.5 years after initiation of anti-TNF-α therapy revealed durable resolution of the pituitary mass. <b>Conclusion:</b> To our knowledge, this is the first report of successful use of anti-TNF-α therapy for a patient with granulomatous hypophysitis, in this case associated with a previous diagnosis of CD. Although glucocorticoids are used frequently as first-line therapy for primary hypophysitis, granulomatous hypophysitis can be corticosteroid resistant and other immunosuppressive approaches may need to be considered within the context of the patient.
BibTeX
@inproceedings{force2020remarkable,
  author = {Bahar Kapoor Force and Tiphanie P. Vogel and Dang Nguyen and Kent A. Heck and Sherly Sebastian and Masayoshi Takashima and Daniel Yoshor and Susan L. Samson},
  title = {{A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease—A Case Report}},
  booktitle = {Frontiers in Endocrinology},
  year = {2020},
  doi = {10.3389/fendo.2020.00350},
}
Figure